Axel Åkerblom

1.7k total citations
42 papers, 1.1k citations indexed

About

Axel Åkerblom is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Nephrology. According to data from OpenAlex, Axel Åkerblom has authored 42 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Cardiology and Cardiovascular Medicine, 17 papers in Surgery and 9 papers in Nephrology. Recurrent topics in Axel Åkerblom's work include Antiplatelet Therapy and Cardiovascular Diseases (13 papers), Acute Myocardial Infarction Research (8 papers) and Chronic Kidney Disease and Diabetes (7 papers). Axel Åkerblom is often cited by papers focused on Antiplatelet Therapy and Cardiovascular Diseases (13 papers), Acute Myocardial Infarction Research (8 papers) and Chronic Kidney Disease and Diabetes (7 papers). Axel Åkerblom collaborates with scholars based in Sweden, United States and United Kingdom. Axel Åkerblom's co-authors include Stefan James, Lars Wallentin, Richard C. Becker, Robert F. Storey, Steen Husted, Philippe Gabríel Steg, Hugo A. Katus, Christopher P. Cannon, Robert A. Harrington and Håkan Emanuelsson and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Journal of the American College of Cardiology.

In The Last Decade

Axel Åkerblom

42 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Axel Åkerblom Sweden 17 745 323 143 142 122 42 1.1k
Elisabetta Ricottini Italy 15 709 1.0× 381 1.2× 194 1.4× 140 1.0× 66 0.5× 60 1.1k
Xavier García–Moll Spain 21 647 0.9× 339 1.0× 171 1.2× 60 0.4× 161 1.3× 83 1.3k
Osamu Hirono Japan 18 782 1.0× 199 0.6× 106 0.7× 48 0.3× 106 0.9× 41 1.2k
Koichi Sagara Japan 22 1.2k 1.7× 233 0.7× 44 0.3× 127 0.9× 77 0.6× 67 1.4k
Murat Çaylı Türkiye 19 800 1.1× 343 1.1× 62 0.4× 145 1.0× 85 0.7× 134 1.4k
Brian A. Moser United States 14 419 0.6× 242 0.7× 131 0.9× 104 0.7× 195 1.6× 24 935
Jinqing Yuan China 18 954 1.3× 681 2.1× 213 1.5× 103 0.7× 133 1.1× 177 1.4k
Hideaki Jinnouchi Japan 15 722 1.0× 372 1.2× 191 1.3× 45 0.3× 273 2.2× 40 1.3k
Nicolas Vignolles France 11 557 0.7× 293 0.9× 143 1.0× 150 1.1× 40 0.3× 13 744
Yuyin Liu United States 18 576 0.8× 378 1.2× 202 1.4× 131 0.9× 94 0.8× 67 1.2k

Countries citing papers authored by Axel Åkerblom

Since Specialization
Citations

This map shows the geographic impact of Axel Åkerblom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Åkerblom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Åkerblom more than expected).

Fields of papers citing papers by Axel Åkerblom

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Åkerblom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Åkerblom. The network helps show where Axel Åkerblom may publish in the future.

Co-authorship network of co-authors of Axel Åkerblom

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Åkerblom. A scholar is included among the top collaborators of Axel Åkerblom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Åkerblom. Axel Åkerblom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Prescott, Eva, Oskar Angerås, David Erlinge, et al.. (2022). Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study. International Journal of Cardiology. 365. 34–40. 8 indexed citations
2.
3.
Prescott, Eva, Oskar Angerås, David Erlinge, et al.. (2021). EFFICACY, SAFETY AND TOLERABILITY OF THE 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITOR AZD5718 IN PATIENTS WITH RECENT MYOCARDIAL INFARCTION: A PHASE 2A STUDY (FLAVOUR). Journal of the American College of Cardiology. 77(18). 136–136. 1 indexed citations
4.
Prescott, Eva, John Pernow, Antti Saraste, et al.. (2020). Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction. Contemporary Clinical Trials Communications. 19. 100629–100629. 9 indexed citations
5.
Oldgren, Jonas, Sanna Laurila, Axel Åkerblom, et al.. (2020). EFFECTS OF 6 WEEKS OF TREATMENT WITH DAPAGLIFLOZIN, A SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR, ON MYOCARDIAL FUNCTION AND METABOLISM IN TYPE 2 DIABETES PATIENTS: A RANDOMIZED PLACEBO-CONTROLLED STUDY. Journal of the American College of Cardiology. 75(11). 1610–1610. 2 indexed citations
6.
Ueland, Thor, Axel Åkerblom, Tatevik Ghukasyan Lakic, et al.. (2019). ALCAM predicts future cardiovascular death in acute coronary syndromes: Insights from the PLATO trial. Atherosclerosis. 293. 35–41. 4 indexed citations
7.
Åkerblom, Axel, Daniel Wojdyla, Philippe Gabríel Steg, et al.. (2019). Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis. 48(4). 563–569. 8 indexed citations
8.
Åkerblom, Axel, Daniel Wojdyla, Lars Wallentin, et al.. (2019). Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal. 213. 57–65. 8 indexed citations
9.
Andersen, Thomas T., Lars Wallentin, Axel Åkerblom, et al.. (2019). CXC MOTIF LIGAND 16: A NOVEL, INDEPENDENT PREDICTOR OF CARDIOVASCULAR DEATH AND MORBIDITY IN ACUTE CORONARY SYNDROMES - A SUBSTUDY OF THE PLATELET INHIBITION AND PATIENT OUTCOMES TRIAL. Journal of the American College of Cardiology. 73(9). 71–71. 1 indexed citations
10.
11.
Evans, Marie, Juan Jesús Carrero, Karolina Szummer, et al.. (2016). Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Myocardial Infarction Patients With Renal Dysfunction. Journal of the American College of Cardiology. 67(14). 1687–1697. 44 indexed citations
12.
Fokkema, Marieke L., Stefan James, Per Albertsson, et al.. (2016). Outcome after percutaneous coronary intervention for different indications: long-term results from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention. 12(3). 303–311. 33 indexed citations
13.
Åkerblom, Axel, Stefan James, H. A. Katus, et al.. (2014). Efficacy and safety of ticagrelor in patients with acute coronary syndrome and heart failure : insights from the platelet inhibition and patient outcomes (PLATO) trial. European Heart Journal. 35. 202–203. 1 indexed citations
14.
Varenhorst, Christoph, Niclas Eriksson, Åsa Johansson, et al.. (2014). TICAGRELOR PLASMA LEVELS BUT NOT CLINICAL OUTCOMES ARE ASSOCIATED WITH TRANSPORTER AND METABOLISM ENZYME GENETIC POLYMORPHISMS. Journal of the American College of Cardiology. 63(12). A25–A25. 7 indexed citations
15.
Hagström, Emil, Niclas Eriksson, Åsa Johansson, et al.. (2013). Are There Any Causal Relations Between Growth Differentiation Factor 15 and Outcomes in Patients With Acute Coronary Syndrome? : - A Report From the Plato Gwas Study. Circulation. 128(22). 2 indexed citations
16.
Fokkema, Marieke L., Stefan James, Per Albertsson, et al.. (2013). Population Trends in Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 61(12). 1222–1230. 112 indexed citations
17.
Åkerblom, Axel, Lars Wallentin, Agneta Siegbahn, et al.. (2011). CYSTATIN C IS AN INDEPENDENT RISK PREDICTOR FOR DEATH OR MYOCARDIAL INFARCTION IN PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) AS WELL AS IN NON-ST-ELEVATION ACUTE CORONARY SYNDROME (NSTE-ACS). Journal of the American College of Cardiology. 57(14). E999–E999. 1 indexed citations
18.
Koutouzis, Michael, Bo Lagerqvist, Jonas Oldgren, et al.. (2010). Long‐Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention. Clinical Cardiology. 33(11). 686–692. 5 indexed citations
19.
20.
Olsson, K. Sigvard, et al.. (1995). Iron deficiency and iron overload in Swedish male adolescents. Journal of Internal Medicine. 237(2). 187–194. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elisabetta Ricottini Breakdown of academic impact, for papers by Xavier García–Moll Breakdown of academic impact, for papers by Osamu Hirono Breakdown of academic impact, for papers by Koichi Sagara Breakdown of academic impact, for papers by Murat Çaylı Breakdown of academic impact, for papers by Brian A. Moser Breakdown of academic impact, for papers by Jinqing Yuan Breakdown of academic impact, for papers by Hideaki Jinnouchi Breakdown of academic impact, for papers by Nicolas Vignolles Breakdown of academic impact, for papers by Yuyin Liu
Rankless by CCL
2026